The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: The Beth Israel Deaconess Medical Center (BIDMC) approach

Cancer Biomarkers

Volumn 4, Issue 4-5, 2008, Pages 251-262

  Bloch, B Nicolas ^a   Lenkinski, Robert E ^a   Rofsky, Neil M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Anterior tumors; Dynamic contrast enhanced MRI; Extracapsular extension; Local recurrence; MR Imaging (MRI); Prostate cancer; Prostate cancer imaging; Repeat negative biopsy; Staging

Indexed keywords

ANTIANDROGEN; BARIUM; GADOLINIUM; GADOLINIUM PENTETATE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER GRADING; CANCER SIZE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRYOSURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; DIGITAL RECTAL EXAMINATION; DISEASE ACTIVITY; EARLY DIAGNOSIS; ECHO PLANAR IMAGING; EXTERNAL BEAM RADIOTHERAPY; FREQUENCY MODULATION; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE PROCESSING; IMAGE QUALITY; IMPOTENCE; INCONTINENCE; INTENSITY MODULATED RADIATION THERAPY; METASTASIS POTENTIAL; MORBIDITY; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SURGERY; QUALITY OF LIFE; QUANTITATIVE DIAGNOSIS; RADIOFREQUENCY ABLATION; RECTUM INJURY; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; THREE DIMENSIONAL IMAGING; TRANSRECTAL ULTRASONOGRAPHY;

EID: 54949122148     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2008-44-507     Document Type: Article

References (86)

1. Leading Sites of New Cancer Cases and Deaths - 2007 Estimates. Cancer Facts & Figures, American Cancer Society 2007.
2. Website ACS. Overview: Prostate Cancer. American Cancer Society, 2004.
3. M. Han, A.W. Partin, S. Piantadosi, J.I. Epstein and P.C. Walsh, Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer, J Urol 166(2) (2001), 416-419.
4. T. Steuber, P.I. Karakiewicz, H. Augustin, A. Erbersdobler, I. Lange, A. Haese, K.H. Chun, J. Walz, M. Graefen and H. Huland, Transition zone cancers undermine the predictive accuracy of Partin table stage predictions, J Urol 173(3) (2005), 737-741.
5. P.D. Sved, P. Gomez, M. Manoharan, S.S. Kim and M.S. Soloway, Limitations of biopsy Gleason grade: Implications for counseling patients with biopsy Gleason score 6 prostate cancer, J Urol 172(1) (2004), 98-102.
6. J.O. Ung, I.F. San Francisco, M.M. Regan, W.C. DeWolf and A.F. Olumi, The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection, J Urol 169(1) (2003), 130-135.
7. I.F. SanFrancisco, M.M. Regan, A.F. Olumi and W.C. DeWolf, Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen, J Urol 171(4) (2004), 1492-1499.
8. A. Krongrad, H. Lai and S. Lai, Variation in prostate cancer survival explained by significant prognostic factors, J Urol 158(4) (1997), 1487-1490.
9. J.W. Moul, Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy, Mol Urol 4(3) (2000), 267-271; discussion 73.
10. A.V.D'Amico, R. Whittington, S.B. Malkowicz, Y.H. Wu, M. Chen, M. Art, J.E. Tomaszewski and A. Wein, Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer, Urology 55(4) (2000), 572-577.
11. K.L. Blackwell, D.G. BOstwick, R.P. Myers, H. Zincke and J.E. Oesterling, Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: The influence of prostate specific antigen cancer density, J Urol 151(6) (1994), 1565-1570.
12. S. Akimoto, M. Masai, K. Akakura and J. ShImazaki, Tumor marker doubling time in patients with prostate cancer: Determination of prostate-specific antigen and prostatic acid phosphatase doubling time, Eur Urol 27(3) (1995), 207-212.
13. M. Tsujy, Y. Murakami, H. Kanayama, T. Sano and S. Kagawa, Immunohistochemical analysis of M-67 antigen and Bcl-2 protein expression in prostate cancer: Effect of neoadjuvant hormonal therapy, Br J Urol 81(1) (1998), 116-121.
14. A.A. Keshgegian, E. Johnston and A. Cnaan, Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma, Am J Clin Pathol 110(4) (1998), 443-449.
15. H. Bonkhoff, T. Fixemer and K. Remberger, Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and?precursors of prostate cancer, Prostate 34(4) (1998), 251-258.
16. G. Ahlgren, K. Pedersen, S. Lundberg, G. Aus, J. Hugosson and P.A. Abrahamsson, Tumor cell proliferation in prostate cancer after 3 months of neoadjuvant LHRH analogue treatment is a prognostic marker of recurrence after radical prostatectomy, Urology 54(2) (1999), 329-334.
17. J.W. Moul, M.C. Bettencourt, I.A. Sesterhenn, F.K. Mostofi, D.G. McLeod, S. Srivastava and J.J. Bauer, Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer, Surgery 120 (2) (1996), 159-166; discussion 66-67.
18. J.L. Bock and G.G. Klee, How sensitive is a prostate-specific antigen measurement? How sensitive does it need to be? Arch Pathol Lab Med 128(3) (2004), 341-343.
19. H.P. Beerlage, Alternative therapies for localized prostate cancer, Curr Urol Rep 4(3) (2003), 216-220.
20. A.R. Zlotta, B. Djavan, C. Matos, J.C. Noel, M.O. Peny, D.E. Silverman, M. Marberger and C.C. Schulman, Percutaneous transperineal radiofrequency ablation of prostate tumour: Safety, feasibility and pathological effects on human prostate cancer, Br J Urol 81 (2) (1998), 265-275.
21. J.P. Long, Cryosurgical ablation of the prostate: Current technique and clinical outcomes, Surg Technol Int 11 (2003), 213-219.
22. C.N. Papandreou and C.J. Logothetis, Bortezomib as a potential treatment for prostate cancer, Cancer Res 64(15) (2004), 5036-5043.
23. K.L. Prepelica, Z. Okeke, A. Murphy and A.E. Katz, Cryosurgical ablation of the prostate: High risk patient outcomes, Cancer 103(8) (2005), 1625-1630.
24. E. Asatiani and E.P. Gelmann, Targeted therapies for prostate cancer, Expert Opin Ther Targets 9(2) (2005), 283-298.
25. J. Kurhanewicz, M.G. Swanson, P.J. Wood and D.B. Vigneron, Magnetic resonance imaging and spectroscopic imaging: Improved patient selection and potential for metabolic intermediate endpoints in prostate cancer chemoprevention trials, Urology 57(4 Suppl 1) (2001), 124-128.
26. E.D. Crawford, W.R. Fair, G.J. Kelloff, M.M. Lieber, G.J. Miller, P.T. Scardino and E.P. DeAntoni, Chemoprevention of prostate cancer: guidelines for possible intervention strategies, J Cell Biochem Suppl 16H (1992), 140-145.
27. L. Wang, M. Mullerad, H.N. Chen, S.C. Eberhardt, M.W. Kattan, P.T. Scardino and H. Hricak, Prostate cancer: Incremental value of endorectal MR imaging findings for prediction of extracapsular extension, Radiology 232(1) (2004), 133-139.
28. C. Mettlin, F. Lee, J. Drago and G.P. Murphy, The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men, Cancer 67 (12) (1991), 2949-2958.
29. E.J. Halpern, F. Frauscher, S.E. Strup, L.N. Nazarian, P. O'Kane and L.G. Gomella, Prostate: High-frequency Doppler US imaging for cancer detection, Radiology 225(1) (2002), 71-77.
30. P.H. Arger, S.B. Malkowicz, K.N. VanArsdalen, C.M. Sehgal, A. Holzer and S.M. Schultz, Color and power Doppler sonography in the diagnosis of prostate cancer: Comparison between vascular density and total vascularity, J Ultrasound Med 23(5) (2004), 623-630.
31. H. Ito, K. Kamoi, K. Yokoyama, K. Yamada and T. Nishimura, Visualization of prostate cancer using dynamic contrast-enhanced MRI: Comparison with transrectal power Doppler ultrasound, Br J Radiol 76(909) (2003), 617-624.
32. K.K. Yu and H. Hricak, Imaging prostate cancer, Radiologic Clinics of North America 38(1) (2000), 59-85, viii.
33. E.S. Siegelman, Magnetic resonance imaging of the prostate, Seminars in Roentgenology 34(4) (1999), 295-312.
34. D. Cheng and C.M. Tempany, MR imaging of thE prostate and bladder. Seminars in Ultrasound, CT & MR 19(1) (1998), 67-89.
35. S.E. Seltzer, D.J. Getty, C.M. Tempany, R.M. Pickett, M.D. Schnall, B.J. McNeil and J.A. Swets, Staging prostate cancer with MR imaging: A combined radiologist-computer system, Radiology 202(1) (1997), 219-226.
36. J.I. Epstein, M.J. Carmichael, G. Pizov and P.C. Walsh, Influence of capsular penetration on progression following radical prostatectomy: A study of 196 cases with long-term fotlowup, J Urol 150(1) (1993), 135-141.
37. B.N. Bloch, N.M. Rofsky, R.H. Baroni, R.P. Marquis, I. Pedrosa and R.E. Lenkinski, 3 Tesla magnetic resonance imaging of the prostate with combined pelvic phased-array and endorectal coils; Initialexperience(1), Acad RAdiol 11(8) (2004), 863-867.
38. C.H. Cunningham, D.B. Vigneron, M. Marjanska, A.P. Chen, D. Xu, R.E. Hurd, J. Kurhanewicz, M. Garwood and J.M. Pauly, Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3T, Magn Reson Med 53(5) (2005), 1033-1039.
39. P.R. Carroll, F.V. Coakley and J. Kurhanewicz, Magnetic resonance imaging and spectroscopy of prostate cancer, Rev Urol 8 (Suppl 1) (2006), S4-S10.
40. A.R Chen, C.H. Cunningham, J. Kurhanewicz, D. Xu, R.E. Hurd, J.M. Pauly, L. Carvajal, K. Karpodinis and D.B. Vigneron, High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence, Magn Reson Imaging 24(7) (2006), 825-832.
41. U.G. Mueller-Lisse, M.G. Swanson, D.B. Vigneron and J. Kurhanewicz, Magnetic resonance spectroscopy in patients with locally confined prostate cancer: Association of prostatic citrate and metabolic atrophy with time on hormone deprivation therapy, PSA level, and biopsy Gleason score, Eur Radiol 17(2) (2007), 371-378.
42. A. Rajesh, F.V. Coakley and J. Kurhanewicz, 3D MR spectroscopic imaging in the evaluation of prostate cancer, Clin Radiol 62(10) (2007), 921-929.
43. A.C. Westphalen, F.V. Coakley, A. Qayyum, M. Swanson, J.P. Simko, Y. Lu, S. Zhao, P.R. Carroll, B.M. Yeh and J. Kurhanewicz, Peripheral Zone Prostate Cancer: Accuracy of Different Interpretative Approaches with MR and MR Spectroscopic Imaging, Radiology (2007).
44. R.G. Gonzalez, P.W. Schaefer, F.S. Buonanno, L.H. Schwamm, R.R Budzik, G. Rordorf, B. Wang, A.G. Sorensen and W.J. Koroshetz, Diffusion-weighted MR imaging: Diagnostic accuracy in patients imaged within 6 hours of stroke symptom onset, Radiology 210(1) (1999), 155-162.
45. P.W. Schaefer, Diffusion-weighted imaging as a problem-solving tool in the evaluation of patients with acute strokelike syndromes, Top Magn Reson Imaging 11(5) (2000), 300-309.
46. Y. Mardor, Y. Roth, Z. Lidar, T. Jonas, R. Pfeffer, S.E. Maier, M. Faibel, D. Nass, M. Hadani, A. Orenstein, J.S. Cohen and Z. Ram, Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging, Cancer Res 61(13) (2001), 4971-4973.
47. S.K. Song, Z. Qu, E.M. Garabedian, J.I. Gordon, J. Milbrandt and J.J. Ackerman, Improved magnetic resonance imaging detection of prostate cancer in a transgenic mouse model, Cancer Res 62(5) (2002), 1555-1558.
48. D. Jennings, B.N. Hatton, J. Guo, J.P. Galons, T.P. Trouard, N. Raghunand, J. Marshall and R.J. Gillies, Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI, Neoplasia 4(3) (2002), 255-262.
49. S.E. Maier, H. Gudbjartsson, S. Patz, L. Hsu, K.O. Lovblad, R.R. Edelman, S. Warach and F.A. Jolesz, Line scan diffusion imaging: characterization in healthy subjects and stroke patients, AJR Am J Roentgenol 171(1) (1998), 85-93.
50. R.L. Robertson, S.E. Maier, R.V. Mulkern, S. Vajapayam, C.D. Robson and P.D. Barnes, MR line-scan diffusion imaging of the spinal cord in children, AJNR Am J Neuroradiol 21(7) (2000), 1344-1348.
51. H. Gudbjartsson, S.E. Maier, R.V. Mulkern, I.A. Morocz, S. Patz and F.A. Jolesz, Line scan diffusion imaging, Magn Reson Med 36(4) (1996), 509-519.
52. B. Issa, In vivo measurement of the apparent diffusion coebficient in normal and malignant prostatic tissues using echoplanar imaging, J Magn Reson Imaging 16(2) (2002), 196-200.
53. D. Strohmeyer, C. Rossing, F. Strauss, A. Bauerfeind, O. Kaufmann and S. Loening, Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer, Prostate 42(1) (2000), 26-33.
54. M. Borre, B.V. Offersen, B. Nerstrom and J. Overgaard, Microvessel density predicts survivaL in prostate cancer patients subjected to watchful waiting, Br J Cancer 78(7) (1998), 940-944.
55. T.A. Fregene, P.S. Khanuja, A.C. Noto, S.K. Gehani, E.M. Van Egmont, D.A. Luz and K.J. Pienta, Tumor-associated angiogenesis in prostate cancer, Anticancer Res 13(6B) (1993), 2377-2381.
56. N. Weidner, P.R. Carroll, J. Flax, W. Blumenfeld and J. Folkam, Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma, Am J Pathol 143(2) (1993), 401-409.
57. M.K. Brawer, R.E. Deering, M. Brown, S.D. Preston and S.A. Bigler, Predictors of pathologic, stage in prostatic carcinoma. The role of neovascularity, Cancer 73(3) (1994), 678-687.
58. M.A. Silberman, A.W. Partin, R.W. Veltri and J.I. Epstein, Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate, Cancer 79(4) (1997), 772-779.
59. M.C. Hall, P. Troncoso, A. Pollack, H.Y. Zhau, G.K. Zagars, L.W. Chung and A.C. von Eschenbach, Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy, Urology 44(6) (1994), 869-875.
60. M.T. Gettman, A. Pacelli, J. Slezak, E.J. Bergstralh, M. Blute, H. ZIncke and D.G. Bostwick, Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma, Urology 54(3) (1999), 479-485.
61. M.A. Rubin, M. Buyyounouski, E. Bagiella, S. Shark, A. Neugut, M. BensOn, A. de la Taille, A.E. Katz, C.A. Olsson and R.D. Ennis, Microvessel density in prostate cancer: Lack of correlation with tumor grade, pathologic stage, and clinical outcome, Urology 53(3) (1999), 542-547.
62. J.W. Moul, Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy, Eur Urol 35 (5-6) (1999), 399-407.
63. H.P. Schlemmer, J. Merkle, R. Grobholz, T. Jaeger, M.S. Michel, A. Werner, J. Rabe and G. van Kaick, Can preoperative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 14(2) (2004), 309-317.
64. G.J. Parker, J. Suckling, S.F. Tanner, A.R. Padhani, P.B. Revell, J.E. Husband and M.O. Leach, Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics, J Magn Reson Imaging 7(3) (1997), 564-574.
65. G.J. Parker, I. Baustert, S.F Tanner and M.O. Leach, Improving image quality and T(1) measurements using saturation recovery turboFLASH with an approximate K-space normalisation filter, Magn Reson Imaging 18(2) (2000), 157-167.
66. P.S. Tofts, Modeling tracer kinetics in dynamic Gd-DTPA MR imaging, J Magn Reson Imaging 7(1) (1997), 91-101.
67. G.J. Parker and P.S. Tofts, Pharmacokinetic analysis of neoplasms using contrast-enhanced dynamic magnetic resonance imaging, Top Magn Reson Imaging 10(2) (1999), 130-142.
68. R.C. Brasch, K.C. Li, J.E. Husband, M.T. Keogan, M. Neeman, A.R. Padhani, D. Shames and K. Turetschek, In vivo monitoring of tumor angiogenesis with MR imaging, Acad Radiol 7(10) (2000), 812-823.
69. E. Furman-Haran, D. Grobgeld, F. Kelcz and H. Degani, Critical role of spatial resolution in dynamic contrast-enhanced breast MRI, J Magn Reson Imaging 13(6) (2001), 862-867.
70. H. Degani, V. Gusis, D. Weinstein, S. Fields and S. Strano, Mapping pathophysiological features of breast tumors by MRI at high spatial resolution, Nat Med 3(7) (1997), 780-782.
71. R.A. Huch Boni, J.A. Boner, J.F. Debatin, F. Trinkler, H. Knonagel, A. Von Hochstetter, U. Helfenstein and G.P. Krestin, Optimization of prostate carcinoma staging: Comparison of imaging and clinical methods, Clin Radiol 50(9) (1995), 593-600.
72. G. Brown, D.A. Macvicar, V. Ayton and J.E. Husband, The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma, Clin RadIol 50(9) (1995), 601-606.
73. G.J. Jager, E.T. Ruijter, C.A. van de Kaa, J.J. De la Rosette, G.O. Oosterhof, J.R. Thornbury, S.H. Ruijs and J.O. Barentsz, Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: Correlation with histopathologic results, RadiOlogy 203(3) (1997), 645-652.
74. S.F Quinn, D.A. Franzini, T.A. DemLow, D.R. Rosencrantz, J. Kim, R.M. Hanna and J. Szumowski, MR imaging of prostate cancer with an endorectal surface coil technique: CorreLation with whole-mount specimens, Radiology 190(2) (1994), 323-327.
75. M.R. Engelbrecht, H.J. Huisman, R.J. Laheij, G.J. Jager, G.J. van Leenders, C.A. Van De Kaa Hulsbergen, J.J. de la Rosette, J.G. Blickman and J.O. Barentsz, Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging, Radiology 229(1) (2003), 248-254.
76. K. Ogura, S. Maekawa, K. Okubo, Y. Aoki, T. Okada, K. Oda, Y. Watanabe, C. Tsukayama and Y. Arai, Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: Correlation with histopathologic results, Urology 57(4) (2001), 721-726.
77. B.N. Bloch, E. Furman-Haran, T.H. Helbich, R.E. Lenkinski, H. Degani, C. Kratzik, M. Susani, A. Haitel, S. Jaromi, L. Ngo and N.M. Rofsky, Accurate Determination of Extracapsular Extension in Prostate Cancer using High Resolution Dynamic Contrast Enhanced and T2W Magnetic Resonance Imaging: Initial Results, Radiology 245 (2007), 176-185.
78. B.N. Bloch, R.E. Lenkinski, T.H. Helbich, L. Ngo, R. Oismueller, S. Jaromi, K. Kubin, R. Hawliczek, I.D. Kaplan and N.M. Rofsky, Prostate postbrachytherapy seed distribution: Comparison of high-resolution, contrast-enhanced, T1- and T2-weighted endorectal magnetic resonance imaging versus computed tomography: Initial experience, Int J Radiat Oncol Biol Phys 69 (2007), 70-78.
79. Y. Rosen, B.N. Bloch, R.E. Lenkinski, R.L. Greenman, R.P. Marquis and N.M. Rofsky, 3T MR of the prostate: Reducing susceptibility gradients by inflating the endorectal coil with a barium sulfate suspension, Magn Reson Med 57(5) (2007), 898-904.
80. R.W. Veltri, M.C. Miller, L.A. Mangold, G.J. O'Dowd, J.I. Epstein and A.W. Partin, Prediction of pathological stage in patients with clinical stage T1c prostate cancer: The new challenge, J Urol 168(1) (2002), 100-104.
81. M. Han and A.W. Partin, Nomograms for clinically localized prostate cancer. Part I: Radical prostatectomy, Semin Urol Oncol 20 (2) (2002), 123-130.
82. A.W. Partin, L.A. Mangold, D.M. Lamm, P.C. Walsh, J.I. Epstein and J.D. Pearson, Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium, Urology 58(6) (2001), 843-948.
83. C.H. Chon, F.C. Lai, J.E. McNeal and J.C. Presti Jr., Use of extended systematic sampling in patients with a prior negative prostate needle biopsy, J Urol 167(6) (2002), 2457-2460.
84. E. Lopez-Corona, M. Ohori, P.T. Scardino, V.E. Reuter, M. Gonen and M.W. Kattan, A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session, J Urol 170 (4 Pt 1) (2003), 1184-1188; discussion 8.
85. Y.M. Hong, F.C. Lai, C.H. Chon, J.E. McNeal and J.C. Presti Jr., Impact of prior biopsy scheme on pathologic features of cancers detected on repeat biopsies, Urol Oncol 22(1) (2004), 7-10.
86. R.E. Lenkinski, B.N. Bloch, F. Liu, J.V. Frangioni, S. Perner, M.A. Rubin, E.M. Genega, N.M. Rofsky and S.M. Gaston, An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression proffies in human prostate cancer, MAGMA (28 Aug 2008). [Epub ahead of print]